Blog | SCA Pharma Leading 503B Outsourcing Facility

SCA Pharma to exhibit at HCP Pharmacy Online Summer Session

EventsBy Wendy Windecker June 11, 2021

SCA Pharma will exhibit at the Health Connect Partners Hospital Pharmacy online summer session and reverse expo June 14-July 1. The conference, which brings together hospital pharmacy decision-makers with suppliers, will allow hospitals to see SCA Pharma’s diverse product portfolio of sterile compounded pharmaceuticals. Visitors to SCA Pharma’s virtual booth can learn more about our quality initiatives and the benefits of outsourcing our…

Details

SCA Pharma connects with customers at HCP conference

EventsBy Wendy Windecker May 11, 2021

SCA Pharma connected with several hospital pharmacy customers during the recently wrapped Health Connect Partners (HCP) Hospital Pharmacy spring virtual conference and reverse expo. We also debuted a new video sharing enhancements to our ordering portal and ordering processes, which help our customers get critical medicines their patients depend on. The annual HCP spring conference…

Details

During National Nurses Month, SCA Pharma recognizes the front-line providers whose work has been critical during the pandemic

NewsBy Wendy Windecker May 7, 2021

SCA Pharma is proud to honor these essential front-line providers during National Nurses Month.

Details

SCA Pharma Appoints Abby Kaplan as General Counsel and Chief Compliance Officer

NewsBy Madeline Drake March 18, 2021

Reflecting its unequivocal commitment to leading the 503B compounded pharmaceuticals outsourcing industry in excellence, SCA Pharmaceuticals has named Abby Kaplan as General Counsel and Chief Compliance Officer.

Details

Ordering portal updates give customers more features

NewsBy Wendy Windecker February 24, 2021

In our ongoing effort to enhance our customers’ experience, SCA Pharma has responded to feedback and made several changes to the customer portal. Here are recent updates: On the home page, customers will find previously published communications, providing easy access to this information. A new interactive catalog is now available by clicking on the SCA…

Details

SCA Pharma extends Beyond Use Dating on many products

503B OutsourcingBy Wendy Windecker February 23, 2021

SCA Pharma’s customers have requested extended Beyond Use Dating (BUD), and we are pleased to help meet their needs by extending BUDs on 69 products to date, while still maintaining our stringent quality controls. We anticipate extending BUDs on most or all of our products. Beyond Use Dating (BUD) on compounded sterile preparations is important…

Details

SCA Pharmaceuticals Appoints Joe Akers as Chief Operating Officer

NewsBy Madeline Drake February 18, 2021

SCA Pharmaceuticals continues its aggressive expansion and implementation of growth strategies, and in doing so, has appointed Joe Akers as Chief Operating Officer.

Details

The indirect costs of risk management for hospital insourcing

503B Outsourcing, OutsourcingBy Wendy Windecker February 15, 2021

This post is our third in a series of blogs looking at how hospitals make the difficult decision to compound their own drugs versus selecting an outsourcing partner. The decision involves a great deal more than a clean room and a vial of medication. A wide range of indirect costs are specifically related to risk…

Details

SCA Pharmaceuticals Appoints Chief Commercial Officer

NewsBy Madeline Drake January 28, 2021

WINDSOR, CONN. (Jan. 28, 2021)– SCA Pharmaceuticals, LLC, announced details last week of their acquisition by The Vistria Group and Excellere. Continuing their strategic growth initiatives, SCA Pharma is announcing the appointment of Mr. Scott Luce as Chief Commercial Officer. Mr. Luce will provide leadership and oversight of commercial operations as SCA Pharma continues to…

Details

The Vistria Group and Excellere Capital Management Invest in SCA Pharmaceuticals

NewsBy Madeline Drake January 21, 2021

WINDSOR, CONN. (Jan. 21, 2021) – SCA Pharmaceuticals, LLC (“SCA Pharma”), has entered into a definitive membership interest purchase agreement with The Vistria Group (“Vistria”) and Excellere Partners (“Excellere”). The Vistria Group and Excellere Partners have purchased all of the issued and outstanding equity interests of SCA Pharma. The terms of the transaction were not…

Details

SCA Pharma Blog